Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegLira versus insulin glargine added to SGLT2 inhibitor therapy in adults with type 2 diabetes
2015-001596-48Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of insulin degludec + liraglutide and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c. Started Jan 2016; status: completed.
02
Drugs
insulin degludec + liraglutideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-001596-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001596-48.